All In Biotech

Drug Trial Radar · NCT06885281

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

166

Planned (sponsor's estimate)

Start

May 12, 2025

Primary completion

Aug 2027

Study completion Apr 2028

Sponsor

Lead sponsor
Zai Lab (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Zai Lab (US) LLC
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Conditions

  • Solid Tumors

Interventions

  • ZL-1310Drug

    drug ZL-1310

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse-Events in Phase 1bTime frame: up to 36 months
  2. Incidence of Serious Adverse Events in Phase 1bTime frame: up to 36 months
  3. Evaluate antitumor activity of ZL-1310 as a single agent in Phase 2Time frame: up to 36 months

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Francisco/Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • OSF St. Francis Medical Center

    Peoria, Illinois · Recruiting

  • Karmanos Cancer Center

    Detroit, Michigan · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • SCRI OP (Oncology Partners)

    Nashville, Tennessee · Recruiting

  • Texas Oncology / Sammons Cancer Center

    Dallas, Texas · Recruiting

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Oncology - Central South

    McAllen, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Gobroad Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.